Table 1.
Demographic and baseline characteristics
| Characteristics | Lansoprazole 15 mg (n=212) | Vonoprazan 10 mg (n=218) | Vonoprazan 20 mg (n=212) |
| Age, years, mean (SD) | 65.2 (10.43) | 65.0 (11.60) | 64.9 (11.37) |
| Gender, n (%) | |||
| Male | 75 (35.4) | 89 (40.8) | 92 (43.4) |
| Female | 137 (64.6) | 129 (59.2) | 120 (56.6) |
| BMI, kg/m2, mean (SD) | 24.1 (4.40) | 24.6 (4.13) | 24.0 (4.02) |
| Underlying chronic disease, n (%) | |||
| Rheumatoid arthritis | 67 (31.6) | 66 (30.3) | 67 (31.6) |
| Osteoarthritis | 75 (35.4) | 92 (42.2) | 65 (30.7) |
| Other | 128 (60.4) | 131 (60.1) | 130 (61.3) |
| NSAID used for long-term therapy, n (%) | |||
| Selective COX-2 inhibitor | 51 (24.1) | 65 (29.8) | 71 (33.5) |
| Other | 161 (75.9) | 153 (70.2) | 141 (66.5) |
| Serum gastrin at screening, pg/mL, mean (SD) | 270.5 (340.04) | 309.2 (377.76) | 320.1 (609.75) |
Serum gastrin at screening by RIA/PEG method. Reference value: 37–172 pg/mL.
BMI, body mass index; COX, cyclo-oxygenase; NSAID, non-steroidal anti-inflammatory drug.
Other NSAIDs used for long-term therapy included: loxoprofen sodium hydrate, meloxicam, diclofenac sodium, etc.